1 - 4 July 2015 Barcelona
![]() |
![]() |
![]() |
![]() |
2-O | Socio-economic status influences likelihood of undergoing surgical treatment for pancreatic cancer in the Netherlands | Maikel Bakens | ![]() |
![]() |
|||
3-PD | Incidence and risk factors of deep venous thrombosis detected by routine surveillance ultrasonography before surgery in patients with gastric cancer | Yutaka Tanizawa | ![]() |
![]() |
|||
4-P | Biomarker-Directed Therapy for Invasive Gastric Cancer: Characterization of a novel regulator of PI3K/AKT/mTOR signaling | SHIKHA SATENDRA SINGH | ![]() |
![]() |
|||
5-O | FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as initial treatment for metastatic colorectal cancer (TRIBE study): updated survival results and final molecular subgroups analyses. | Chiara Cremolini | ![]() |
![]() |
|||
7-PD | Clinical outcome of Endoscopic Resection of Rectal Neuroendocrine Tumor- NET registry multicenter study | Young Kwan Cho | ![]() |
![]() |
|||
7-O | Neuropilin 1 (NRP1) may be Prognostic and Identify a Subgroup of Patients with Metastatic Colorectal Cancer (mCRC) who Benefit from Tivozanib mFOLFOX6 compared to Bevacizumab mFOLFOX6. | Michael Needle | ![]() |
![]() |
|||
8-PD | Safety and efficacy of desensitization protocols for platinum hypersensitivity reactions | Katrina Pedersen | ![]() |
![]() |
|||
8-O | Phase II Study of Tivantinib (ARQ 197) in Combination with Cetuximab in EGFR Inhibitor-resistant, MET-High, KRAS Wild-Type (KRASwt) Metastatic Colorectal Cancer (mCRC) | Lorenza Rimassa | ![]() |
![]() |
|||
9-PD | Use of adjuvant chemotherapy after pancreatoduodenectomy for pancreatic cancer: a nationwide population-based study in the Netherlands | Maikel Bakens | ![]() |
![]() |
|||
10-O | KRAS and BRAF gene subgroup analysis in the Phase 3 RECOURSE trial of TAS-102 versus placebo in patients with metastatic colorectal cancer | Howard Hochster | ![]() |
![]() |
|||
11-O | Characteristics and outcomes of patients enrolled in the CORRECT and CONCUR phase 3 trials of regorafenib for metastatic colorectal cancer (mCRC) | Axel Grothey | ![]() |
![]() |
|||
11-PD | Inexpensive biomarkers for determining individuals at increased risk for colorectal cancer and hence have the repeat screening colonoscopy after the first normal earlier than guidelines recommend | Garry Mahon | ![]() |
![]() |
|||
11-P | ARHI re-expression inhibits subcutaneous xenograft growth and the lung/liver metastases of human gastric cancer cells (BGC823) in nude mice | JINGPING QIU | ![]() |
![]() |
|||
13-PD | A study level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors vs bevacizumab in patients with metastatic colorectal cancer | Dawn Batty | ![]() |
![]() |
|||
14-P | A Tumor-penetrating Recombinant Protein anti-EGFR-iRGD Enchance Efficacy of Paclitaxel in 3D multicellular spheroids and Gastric Cancer in vivo | huizi sha | ![]() |
![]() |
|||
14-PD | First-line treatment with modified FOLFOX6 (mFOLFOX6) panitumumab or bevacizumab in patients with RAS/BRAF wild-type metastatic colorectal carcinoma | Dawn Batty | ![]() |
![]() |
|||
14-O | High BRAF mutation frequency and marked survival differences in subgroups according to KRAS/BRAF mutation status and tumor tissue availability in a prospective population-based metastatic colorectal cancer cohort. | Halfdan Sorbye | ![]() |
![]() |
|||
15-PD | A survey on current RAS-mutation testing practices in Europe | Emma Earnshaw | ![]() |
![]() |
|||
16-O | Exploratory analysis of tumor growth rate in patients with advanced gastrointestinal stromal tumors (GIST) treated with regorafenib in the GRID phase 3 trial | Christian Kappeler | ![]() |
![]() |
|||
17-PD | A multicenter phase I/II study of TAS-102 with bevacizumab for metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE) | Tomohiro Nishina | ![]() |
![]() |
|||
18-P | Desacetyl isovaltratum, an extract from Valeriana, induces G2/M phase arrest and apoptosis in gastric cancer cell lines | Bo Zhang | ![]() |
![]() |
|||
18-PD | Modifiable risk factors for colorectal cancer: a multinational case-control study | Borys Hrinczenko | ![]() |
![]() |
|||
22-P | Expression of Circulating Annexin A2 in Hepatic Diseases and Hepatocellular Carcinoma | Ebtesam Elgezawy | ![]() |
![]() |
|||
25-P | Long non-coding RNA AOC4P suppressed hepatocellular carcinoma metastasis by inhibiting epithelial-mesenchymal transition | Tong-Hong Wang | ![]() |
![]() |
|||
29-P | NEUROENDOCRINE TUMORS (NETs). RESPONSE TO CHEMOTHERAPY BY HISTOLOGICAL GRADE. EXPERIENCE CENTER. | Cynthia Scarlet Gonzalez Rivas | ![]() |
![]() |
|||
33-P | Fruit consumption and ed gastrointestinal cancers morbidity in Poland in the years 1990-2012 | Miroslaw Jarosz | ![]() |
![]() |
|||
34-P | Red meat consumption and ed gastrointestinal cancers morbidity in Poland in the years 1990-2012 | Miroslaw Jarosz | ![]() |
![]() |
|||
35-P | P11 is a potential prognostic marker in pancreatic cancer patients and contributes to cancer cell invasion | Moamen Bydoun | ![]() |
![]() |
|||
36-P | Phase II study of Gemcitabine and Curcumin (Meriva) as first line treatment for locally advanced or metastatic pancreatic cancer: preliminary data. | Caterina Soldà | ![]() |
![]() |
|||
39-P | Increased expression of monocarboxylate transporters 1 and 4 and carbonic anhydrase IX in pancreatic ductal adenocarcinomas | Ana Marques | ![]() |
![]() |
|||
41-P | PATTERNS OF FAILURE IN PANCREATIC CANCER: RESULTS REVIEW | M Victoria De Torres Olombrada | ![]() |
![]() |
|||
42-P | Institutional experience in induction chemotherapy and neoadjuvant IMRT for borderline resectable and locally advanced pancreatic adenocarcinoma | M Victoria De Torres | ![]() |
![]() |
|||
44-P | Preoperative chemoradiotherapy in locally advanced esophageal carcinoma: Data from a multidisciplinary oncologic center. | Maria Saigi Morgui | ![]() |
![]() |
|||
47-P | Perioperative chemotherapy (ECF/FLOT/EOX) for esophagogastric adenocarcinoma: Impact of postoperative chemotherapy on outcome | Jens Hoeppner | ![]() |
![]() |
|||
50-P | The role of radiotherapy or chemoradiotherapy for oligo-reccurence of esophageal cancer after curative resection or chemoradiotherapy | Toshihiko Matsumoto | ![]() |
![]() |
|||
51-P | Is Minimally Invasive Esophagectomy Oncologically Safe? Results of a Case-Control Study | MARISA ARAL | ![]() |
![]() |
|||
52-P | Outcomes of Minimally Invasive Esophagectomy versus Open Esophagectomy for Esophageal Cancer: a Single-Center Case-Control Study | MARISA ARAL | ![]() |
![]() |
|||
53-P | MET Overexpression and Amplification Define a Distinct Molecular Subgroup for Targeted Therapies in Gastric Cancer | Jia Wei | ![]() |
![]() |
|||
54-P | Evaluation of driver mutations involving in RAS-RAF/PI3K-mToR pathway in gastric signet ring cell carcinoma | Baorui Liu | ![]() |
![]() |
|||
55-P | High BIM mRNA levels associated with longer survival in advanced gastric cancer | Nandie Wu | ![]() |
![]() |
|||
59-P | Can high levels of preoperative carbohydrate antigen 19-9 be a predictor of survival in gastric cancer? | Ana Rita Garcia | ![]() |
![]() |
|||
60-P | Intestinal versus Diffuse Gastric Cancer Chemoradiation for all or do we need different therapeutic approaches? | Ana Rita Garcia | ![]() |
![]() |
|||
70-P | Phase I dose-finding study of S-1 in combination with docetaxel and oxaliplatin (DOS) as first-line therapy in patients with advanced gastro-esophageal cancer. | Per Pfeiffer | ![]() |
![]() |
|||
77-P | TRIGGER FACTOR IN STOMACH MALT-LYMPHOMA | Makhsud Mallaev | ![]() |
![]() |
|||
78-P | SMALL CELL STOMACH MALT-LYMPHOMA | Makhsud Mallaev | ![]() |
![]() |
|||
79-P | Impact of disease biology and stage on outcomes for oesophageal and gastric adenocarcinoma (OGA) treated with neoadjuvant chemotherapy. | Elisa Fontana | ![]() |
![]() |
|||
80-P | STAGING ECHOENDOSCOPY IN ESOPHAGOGASTRIC CANCER PATIENTS ONGOING SURGERY | Ana Villaescusa | ![]() |
![]() |
|||
81-P | Serum tumor markers as predictors of overall response rate and clinical benefit in patients with advanced esophagogastric adenocarcinoma (EGA) treated with chemotherapy | Silvia Patricia Cortez Castedo | ![]() |
![]() |
|||
83-P | Prognostic determinants in gastric cancer survival - the importance of metastatic lymph node ratio | Amanda Nogueira | ![]() |
![]() |
|||
84-P | GASTRIC CANCER - THE REALITY OF AN INSTITUTION | Nadine Saraiva | ![]() |
![]() |
|||
86-P | Trastuzumab induced cardiotoxicity in Her2 positive metastatic oeso-gastric cancers | Jerome MARTIN-BABAU | ![]() |
![]() |
|||
88-P | Evaluation of prognostic and predictive factors in second-line treatment with irinotecan based chemotherapy in gastric cancer. | Renata Biernacka | ![]() |
![]() |
|||
89-P | TREATMENT OF METASTATIC GASTRIC CANCER WITH DOCETAXEL-IRINOTECAN COMBINATION. VIRGEN DE LAS NIEVES UNIVERSITY HOSPITAL EXPERIENCE. | VERONICA CONDE HERRERO | ![]() |
![]() |
|||
93-P | HER2 protein over-expression in early stage gastric cancer: correlation with clinicopathological features and survival. | Tugba Yavuzsen | ![]() |
![]() |
|||
94-P | FDG PET/CT AS A PREOPERATIVE STAGING MODALITY FOR EARLY GASTRIC CANCER. | Hyungwoo Oh | ![]() |
![]() |
|||
97-P | Double tract reconstruction after laparoscopic proximal gastrectomy; its procedure and short-term results | Kazuyuki Kojima | ![]() |
![]() |
|||
98-P | LOCAL ADVANCED GASTRIC CANCER: OPTIMIZATION OF MANAGEMENT | Oleg Kshivets | ![]() |
![]() |
|||
99-P | THE FREQUENCY OF POSITIVE PERITONEAL WASHING IN PATIENTS WITH T4a STAGE GASTRIC CANCER: LONG-TERM RESULTS OF RADICAL SURGERY | Ramiz Bayramov | ![]() |
![]() |
|||
102-P | Results of surgical therapy for loco-regional recurrence of gastric cancer | Anna Chayka | ![]() |
![]() |
|||
107-P | Topoisomerase II Alpha (TopoIIa) As A Prognostic Biomarker In Hepatocellular Carcinoma | Heba El Zawahry | ![]() |
![]() |
|||
108-P | Systematic evaluation of serum inflammatory markers for prognostication of hepatocellular carcinoma (HCC) | Lam Chan | ![]() |
![]() |
|||
112-P | Local combination therapy with chemoembolization and microwave ablation in patients with Hepatocellular Carcinoma a single center experience. | Hermina Fernandes | ![]() |
![]() |
|||
114-P | A phase II trial of bevacizumab and erlotinib as second line therapy for advanced hepatocellular carcinoma | Ahmed Kaseb | ![]() |
![]() |
|||
115-P | Transarterial Chemo-Embolization (TACE) and Radio-Embolization (TARE) in the combined modality treatment of advanced biliary tract cancer (aBTC): evaluation of feasibility and activity. | Valentina Angela Marsico | ![]() |
![]() |
|||
116-P | Phase 1 Study of PV-10 for Chemoablation of Hepatocellular Cancer and Cancer Metastatic to the Liver | Eric Wachter | ![]() |
![]() |
|||
117-P | Sarcopenia at First Diagnosis Predicts a Reduced Survival in Patients Affected by Hepatocarcinoma | Paola Begini | ![]() |
![]() |
|||
122-P | Concurrent Chemotherapy and Volumetric Modulated Arc Therapy (VMAT ) in carcinoma of the anal canal- Reduction of acute gastrointestinal and genitourinary toxicity | kaloyan yordanov | ![]() |
![]() |
|||
123-P | Prognostic factors for disease relapse in patients with neuroendocrine tumours who underwent curative surgery | Astrid Slagter | ![]() |
![]() |
|||
127-P | Efficacy of Y-Shaped Bilateral Self-Expandable Metallic Stent Placement in Patients with Unresectable Hilar Cholangiocarcinoma | Jong Jin Hyun | ![]() |
![]() |
|||
128-P | Efficacy of Various Endoscopic Transpapillary Sampling Methods for Malignant Biliary Lesions | Jong Jin Hyun | ![]() |
![]() |
|||
129-P | Cisplatin plus Gemcitabine in Elderly patients with advanced biliary tract carcinoma: Torrecardenas Hospital Experience. | CASTELLÓN RUBIO VICTORIA EUGENIA | ![]() |
![]() |
|||
130-P | Predictors of malignancy in biliary mucin-producing cystic neoplasms | Sung Yong Han | ![]() |
![]() |
|||
141-P | Combined versus sequential adjuvant therapy of biliary tract cancer: what is the best option? | Alessandra Cassano | ![]() |
![]() |
|||
143-P | Weight Loss during chemotherapy in patients with advanced Oesophagogastric (OG) and Hepatobiliary-Pancreatic (HPB) cancers is not a surrogate for disease progression. | GEORGIOS OIKONOMOPOULOS | ![]() |
![]() |
|||
145-P | Prospective Phase II Trial of Combination Treatment of Whole Hepatic Irradiation and Hyperthermia in Chemorefractory Numerous Hepatic Metastases of Gastrointestinal Malignancy | Jeong Il Yu | ![]() |
![]() |
|||
146-P | STENTING METASTATIC BILE DUCT OBSTRUCTION (BDO): THE IMPORTANCE OF LIVER FUNCTION PARAMETERS | Milana Bergamino Sirvén | ![]() |
![]() |
|||
153-P | Impact of comorbidity on the survival of patients with cholangiocarcinoma | Elizabeth Inga | ![]() |
![]() |
|||
156-P | Biliary drainage in patients with extrahepatic bile ducts cancer and obstructive jaundice | Vladislav Stoyanov | ![]() |
![]() |
|||
157-P | Mitomycin C, 5-Fluorouracyl and Doxorubicin combination as a second-line chemotherapy in unresectable and metastatic biliary tract carcinoma: results of the first stage | Agata Kuchar | ![]() |
![]() |
|||
159-P | Gastric myoelectric activity disturbances in patients with gastric and colorectal cancer. Preliminary study. | Zygulska Aneta | ![]() |
![]() |
|||
160-P | Estimation of autonomic nervous system activity by heart rate and blood pressure variability in patients with gastric and colorectal cancer. Preliminary study. | Aneta Zygulska | ![]() |
![]() |
|||
161-P | A phase I-trial assessing several schedules of Oral S-1 combined with fixed doses of Oxaliplatin and Irinotecan in patients with advanced or metastatic digestive adenocarcinoma as first- or second-line treatment. | Emmanuelle SAMALIN | ![]() |
![]() |
|||
162-P | Interim Results of IMMU-132 (Sacituzumab Govitecan), an Anti-Trop-2 Antibody-Drug Conjugate (ADC), in Patients (pts) with Metastatic Gastrointestinal (GI) Cancers. | Arlene Powell | ![]() |
![]() |
|||
163-P | Is KRAS status prognostic or predictive for anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer? | Hironaga Satake | ![]() |
![]() |
|||
164-P | GEMCITABINE VERSUS FOLFIRINOX IN PATIENTS WITH ADVANCED PANCREATIC ADENOCARCINOMA HENT1 POSITIVE: BACK TO THE FUTURE. | Maria Alessandra Calegari | ![]() |
![]() |
|||
166-P | Decrement of Serum CA 19-9 Concentration after Initial Chemotherapy Predicts Favorable Outcome in Patients with Advanced Pancreatic Cancer | JIKON RYU | ![]() |
![]() |
|||
167-P | Risk factors for febrile neutropenia in patients with unresectable pancreatic cancer receiving FOLFIRINOX as the first-line treatment. | Mitsuhito Sasaki | ![]() |
![]() |
|||
168-P | Definitive 3D concurrent chemoradiotherapy in locally advanced pancreatic cancer | Abdelgawad Marwa | ![]() |
![]() |
|||
172-P | Efficacy and safety of S-1 and gemcitabine in an uned Western cohort of patients with unresectable pancreatic cancer. | Per Pfeiffer | ![]() |
![]() |
|||
174-P | The role of gastroenterologists in providing initial information on treatment options for patients with pancreatic cancer (PC) in the United States and Europe: a global quantitative survey | Andrew Rhim | ![]() |
![]() |
|||
177-P | Phase II trial of capecitabine nab-paclitaxel in patients with metastatic pancreatic adenocarcinoma | Werner Scheithauer | ![]() |
![]() |
|||
178-P | First-line chemotherapy with gemcitabine in advanced pancreatic cancer: a retrospective single-center analysis | Helena Magalhaes | ![]() |
![]() |
|||
179-P | Gemcitabine plus nab-Paclitaxel in metastatic or locally inoperable pancreatic cancer a single center experience | Ursula Vogl | ![]() |
![]() |
|||
183-P | NEOADJUVANT TREATMENT IN BORDERLINE RESECTABLE PANCREATIC ADENOCARCINOMA: A SINGLE CENTER SERIES | Helena Verdaguer Mata | ![]() |
![]() |
|||
184-P | nab-Paclitaxel (nab-P) plus gemcitabine (Gem) for patients with advanced pancreatic cancer who have cholestatic hyperbilirubinemia (CH) secondary to bile duct obstruction: a phase I safety and pharmacokinetics study | Hanno Riess | ![]() |
![]() |
|||
185-P | Randomized phase III trial of nab-paclitaxel (nab-P) plus gemcitabine (Gem) vs Gem alone as adjuvant therapy for patients with resected pancreatic cancer: APACT | Margaret Tempero | ![]() |
![]() |
|||
186-P | International phase II trial of weekly nab-paclitaxel (nab-P) plus gemcitabine (Gem) in patients with locally advanced pancreatic cancer (LAPC): LAPACT | Philip Philip | ![]() |
![]() |
|||
190-P | Feasibility of using MicroRNAs in early detection of recurrence in colon cancer patients | Jesper Olsen | ![]() |
![]() |
|||
193-P | Downregulation of CDX2 is associated with MMR-deficiency but not recurrence in colon cancer | Jesper Olsen | ![]() |
![]() |
|||
195-P | SPRY2 AND RESPONSE TO FOLFOX/CAPOX IN METASTATIC KRAS MUTATED COLORECTAL CANCER | Robert Montal | ![]() |
![]() |
|||
197-P | Number of CD68() macrophages and FasL expression in colon mucosa of patients with inflammatory bowel disease as prognostic factors of colon carcinogenesis | Andrei Santimov | ![]() |
![]() |
|||
198-P | Circulating microRNAs in metastatic colorectal cancer (mCRC) patients (pts) treated with regorafenib. | Marta Schirripa | ![]() |
![]() |
|||
206-P | Efficacy and tolerance of a simplified combination of Streptozotocine and epi-adriamycine in metastatic foregut neuroendocrine tumor (NET). | Laure Hirsch | ![]() |
![]() |
|||
212-P | The cost of survival gain in metastatic colorectal cancer (mCRC) in France | Whalen John | ![]() |
![]() |
|||
213-P | The cost of survival gain in metastatic colorectal cancer (mCRC) in Spain | John Whalen | ![]() |
![]() |
|||
214-P | Pattern of Dipkoff-2 gene expression in tumoral tissues of colorectal cancer and two tumor tissues of colorectal cancer and three cell lines (HUVEC, SW480 and HCT116) | Farnaz Khodarahmi | ![]() |
![]() |
|||
216-P | Effect on colorectal cancer patients anxiety levels of planned following at home | Ilknur Aydin Avci | ![]() |
![]() |
|||
222-P | Detection of colorectal dysplasia using fluorescently-labeled lectins | Joe C Kuo | ![]() |
![]() |
|||
223-P | The first experience in Intraoperative Radiation Therapy for locally advanced or recurrent rectal cancer | Sergey Potemin | ![]() |
![]() |
|||
229-P | BODY FAT MASS AND THE RISK OF COLORECTAL POLYPS IN MEN AND WOMEN | Miroslaw Jarosz | ![]() |
![]() |
|||
230-P | Cost effectiveness of Selective Internal Radiation Therapy (SIRT) using yttrium-90 resin microspheres for the treatment of patients with inoperable colorectal liver metastases in France | Karin Sennfalt | ![]() |
![]() |
|||
233-P | Economic impact of biomarker-based anti EGFR therapies in metastatic colorectal cancer in Austria | Dora Nieders-Beke | ![]() |
![]() |
|||
234-P | The Intestinal Stem Cell Marker SOX9 Predicts Relapse of Stage II Colon Cancer Patients | Maiken Lise Marcker Espersen | ![]() |
![]() |
|||
235-P | Retrospective evaluation of ADCC activity and cetuximab response in KRAS wild-type metastatic colorectal cancer patients (mCRC) | Vincenzo Ricci | ![]() |
![]() |
|||
236-P | Other RAS mutations incidence in CRCm in routine clinical practice: a center experience. | Beatriz González | ![]() |
![]() |
|||
237-P | K-RAS exon 2 mutations in advanced colorectal cancer: are they really so bad prognostic indicators? A mono-insititutional retrospective study | Vincenzo Dadduzio | ![]() |
![]() |
|||
238-P | Circulating epidermal growth factor-like domain 7 of prognostic importance in patients with metastatic colorectal cancer | Torben Hansen | ![]() |
![]() |
|||
240-P | Did the mRNA cutoff copy numbers in peripheral blood influence their relationship with prognosis in stage I-III colorectal cancer patients | Yong Liu | ![]() |
![]() |
|||
241-P | FEASIBILITY AND RESULTS OF EXPANDED RAS GENOTIPYNG IN AN ARGENTINEAN PUBLIC HOSPITAL | Silvina Otero | ![]() |
![]() |
|||
244-P | Prospective study of S-1Irinotecan plus bevacizumab as second-line therapy in Japanese patients with metastatic colorectal cancer (KSCC1102) | Hironaga Satake | ![]() |
![]() |
|||
245-P | Cetuximab with infusional or oral fluorouracil in 1st line treatment for metastatic colorectal cancer: a comparison study | Hironaga Satake | ![]() |
![]() |
|||
246-P | Feasibility study of sequential adjuvant chemotheraphy with three months oxaliplatin-based regimen followed by three months capecitabine in patients with stage III and high risk stage II colorectal cancer: (JSWOG C2) | Hiroaki Tanioka | ![]() |
![]() |
|||
250-P | Clinical Impact and Cost Implication of Routine MMR Protein Immunohistochemistry in High Risk Dukes B Colon Cancer | Kevin Chiu | ![]() |
![]() |
|||
254-P | A multicentre, non-interventional, post-authorization study to observe in daily clinical practice the treatment duration of patients treated with bevacizumab in 1st line mCRC in Belgium. | Dieter Frijns | ![]() |
![]() |
|||
255-P | A randomized, placebo-controlled, double-blind phase II trial of peri-operative cimetidine in early colorectal cancer | Michael Jameson | ![]() |
![]() |
|||
256-P | An open-label trial to assess the safety of regorafenib in Turkish patients with metastatic colorectal cancer (mCRC) that progressed on standard therapy (REGARD) | faysal dane | ![]() |
![]() |
|||
257-P | Intensity of adjuvant chemotherapy regimens among elderly stage III colon cancer patients | Felice van Erning | ![]() |
![]() |
|||
258-P | Grade III-IV toxicities among elderly stage III colon cancer patients receiving CAPOX or capecitabine | Felice van Erning | ![]() |
![]() |
|||
259-P | Recurrence-free survival according to treatment modality among elderly stage III colon cancer patients | Felice van Erning | ![]() |
![]() |
|||
261-P | Pharmacokinetics of regorafenib in the phase 3 CONCUR and CORRECT trials in patients with metastatic colorectal cancer (mCRC) | Isrid Sturm | ![]() |
![]() |
|||
266-P | Aflibercept as a second line chemotherapy in metastatic colorectal cancer. One centre experience. | Beatriz González | ![]() |
![]() |
|||
267-P | Systemic therapy and surgery improve overall survival compared with surgery alone after curative liver resection of colorectal metastases: a single-center study from Costa Rica | Allan Ramos-Esquivel | ![]() |
![]() |
|||
270-P | Regorafenib for metastatic colorectal cancer in community setting: a multicenter retrospective analysis in Hong Kong | Ka-On LAM | ![]() |
![]() |
|||
271-P | Retrospective Cohort Study on the Safety and Efficacy of Regorafenib for Metastatic Colorectal Cancer Patients : The HGCSG1401 Study -First Report- | SATOSHI YUKI | ![]() |
![]() |
|||
272-P | Phase II study of Regorafenib as single agent for the treatment of patients with metastatic colorectal cancer with any RAS or BRAF mutation and previously treated with FOLFOXIRI plus bevacizumab | Susana Rodríguez | ![]() |
![]() |
|||
273-P | Concordance of RAS mutation status in CRC patients by comparison of results from circulating tumour DNA and tissue-based testing | Rodney Scott | ![]() |
![]() |
|||
274-P | Nodal status predict pathologic complete response following preoperative chemotherapy for colorectal liver metastases | LOURDES CALERA | ![]() |
![]() |
|||
275-P | Phase II study of oral tegafur/uracil and leucovorin plus bevacizumab as a first line therapy for elderly patients with advanced or metastatic colorectal cancer | Hiroshi Tamagawa | ![]() |
![]() |
|||
276-P | S-1 and oxaliplatin (SOx) in older Western patients with metastatic colorectal cancer (mCRC) | Per Pfeiffer | ![]() |
![]() |
|||
277-P | Increased Carcinoembryonic antigen (CEA) predicts poor prognosis in patients after neoadjuvant chemotherapy that undergo hepatectomy for liver-only colorectal metastases and especially in those who dont receive post-hepatectomy adjuvant chemotherapy | Mafalda Costa Neves | ![]() |
![]() |
|||
279-P | CETUXIMAB AS THIRD LINE TREATMENT OF METASTATIC COLORECTAL CARCINOMA (mCRC) 5-YEAR EXPERIENCE FROM THE INSTITUTE OF ONCOLOGY AND RADIOLOGY OF SERBIA | Jelena Spasic | ![]() |
![]() |
|||
281-P | The GERCOR and Khne prognostic models in metastatic colorectal cancer (mCRC) patients treated with bevacizumab-based first-line therapy: comparison and validation of both models in a real-life setting | Gema Bruixola | ![]() |
![]() |
|||
282-P | Palliative chemotherapy for patients 70 and above with metastatic colorectal cancer: How Much Chemotherapy is Enough? | Dominick Bossé | ![]() |
![]() |
|||
283-P | Impact of second-line cetuximab-containing therapy in patients with KRAS wild type metastatic colorectal cancer: results from ITACa trial. | alessandro passardi | ![]() |
![]() |
|||
284-P | Phase 3 RECOURSE trial of TAS-102 versus placebo with best supportive care in patients with metastatic colorectal cancer: European subgroup | Alfredo Falcone | ![]() |
![]() |
|||
285-P | Treatment of metastatic colorectal cancer. Experience of Centro Javeriano de Oncología - Hospital Universitario San Ignacio, Bogotá, Colombia | Annie Katherine Natera Melo | ![]() |
![]() |
|||
292-P | The Polyp Manager: a new tool to report polyps during colonoscopy in a complete and time efficient way. A pilot study. | Maartje van de Meeberg | ![]() |
![]() |
|||
295-P | CA 11-19: A Tumor Marker to Detect Colorectal Cancer | lisa jensen-long | ![]() |
![]() |
|||
296-P | Preventive intraperitoneal chemotherapy in colon cancers with high risk of recurrence: outcome at 5 years from a prospective study | Anissa Ourabah | ![]() |
![]() |
|||
297-P | Anastomotic leakage in patients operated for colorectal cancer in a high volume UK centre within an enhanced recovery programme setting | Jimmy Ng | ![]() |
![]() |
|||
298-P | Perioperative Oral Nutritional Support in Colorectal Cancer Patients May Improve Clinical and Health Economics Outcomes | Viktor Manasek | ![]() |
![]() |
|||
299-P | Contrast medium marking for gastrointestinal stenting | Jun Ninomiya | ![]() |
![]() |
|||
304-P | RECORA - A national non-interventional study to assess efficacy and safety of regorafenib in patients with metastatic colorectal cancer (mCRC) after failure of standard therapy. | Phillip Strauss | ![]() |
![]() |
|||
305-P | A phase II biopsy-driven study to identify biomarkers predictive of clinical response to second-line regorafenib in patients with metastatic colorectal cancer | Anna Schab | ![]() |
![]() |
|||
306-P | A Phase Ib Biomarker Trial of Naproxen in Patients at Risk for DNA Mismatch Repair Deficient Colorectal Cancer | Eduardo Vilar | ![]() |
![]() |
|||
311-P | A prospective, observational trial to assess the safety and efficacy of regorafenib in patients with metastatic colorectal cancer (mCRC) in routine clinical practice (CORRELATE) | Michel Ducreux | ![]() |
![]() |
|||
313-P | K-ras mutation as prognostic factor in our patients with rectal cancer | Danijela Scepanovic | ![]() |
![]() |
|||
317-P | Outcome of elderly patients with non-metastatic rectal cancer: a retrospective study | Marc-André Bureau | ![]() |
![]() |
|||
319-P | Angiogenesis evaluation in locally advanced colo-rectal and gastric cancers by probe-based Confocal Laser Endomicroscopy (pCLE) | Renato Cannizzaro | ![]() |
![]() |
|||
322-P | CONCOMITENT RADIOCHEMOTHERAPY IN ELDERLY PATIENTS WITH LOCALLY-ADVANCED RECTAL CANCER | Rodica Anghel | ![]() |
![]() |
|||
323-P | CISPLATIN PLUS CAPECITABINE (CisCape) AND RADIOTHERAPY (RT) FOR THE NEOADJUVANT TREATMENT OF RECTAL CANCER: FINAL UPDATE OF PREVIOUSLY REPORTED DATA | Laura Martano | ![]() |
![]() |
|||
325-P | A Phase II trial using a combination of Oxaliplatin, Capecitabine, and Celecoxib with concurrent radiation for newly diagnosed resectable rectal cancer: COX2 expression in relationship to outcomes | Emilio Araujo-Mino | ![]() |
![]() |
|||
327-P | BIOLOGIC THERAPY IN THE MANAGEMENT OF LOCALLY ADVANCED RECTAL CANCER, EXPERIENCE OF 20 DE NOVIEMBRE ISSSTE MEDICAL CENTER, MEXICO CITY | Josue Mora Perez | ![]() |
![]() |
|||
328-P | Which is the best first approach for liver-only synchronic metastasis rectal cancer? | Ismael Ghanem | ![]() |
![]() |
|||
329-P | Reintroduction of oxaliplatin for patients with metastatic colorectal cancer | Marija Ristic | ![]() |
![]() |
|||
331-P | Organ sparing radiotherapy in rectal cancer: definitive chemoradiation is a safe and valid option. | Rachel Brooker | ![]() |
![]() |
|||
334-P | RADIOLOGICAL ASSESSMENTS FOR SELECT PATIENTS IN NEOADJUVANT SETTING IN RECTAL CANCER: MONOISTITUTIONAL EXPERIENCE | roberto murialdo | ![]() |
![]() |
|||
338-P | Non-Operative Treatment after Neo-Adjuvant Short Course Radiotherapy (The Tlalpan Regime) in a combined modality for Locally Advanced Rectal Cancer with risk factors at the Instituto Nacional de Cancerología (México) | Jesus Zamora-Moreno | ![]() |
![]() |
|||
340-P | Value of Pelvic Index for prediction of anastomotic leakage after laparoscopic low anterior resection in male rectal cancer | ATSUSHI TSURUTA | ![]() |
![]() |
|||
342-P | Standardized Technique of Laparoscopic Extralevator Abdominoperineal Excision (LAP-ELAPE) | Madoka Hamada | ![]() |
![]() |
THE SUBMISSION DEADLINE HAS BEEN EXTENDED UNTIL MONDAY 6TH JULY AT 23:00 GMT+1. |
---|
![]() |
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. ![]() To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress. ![]() |
![]() |
||
![]() |
|